2-[isopropyl(methyl)amino]-6-nitro-1H-benzimidazole | 652979-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[isopropyl(methyl)amino]-6-nitro-1H-benzimidazole
• 英文别名: N-methyl-6-nitro-N-propan-2-yl-1H-benzimidazol-2-amine
• CAS: 652979-67-4
• 化学式: C₁₁H₁₄N₄O₂
• 分子量: 234.258
• InChiKey: HBMNAZMZBKLIRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  77.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[isopropyl(methyl)amino]-6-nitro-1H-benzimidazole 在 Pearlman's catalist 、 氢气 作用下， 以 甲醇 为溶剂， 生成 6-amino-2-[isopropyl(methyl)amino]-1H-benzimidazole
  参考文献：
  名称：

  Identification of 2-aminobenzimidazoles as potent melanin-concentrating hormone 1-receptor (MCH1R) antagonists

  摘要：

  A series of 2-aminobenzimidazole-based MCH1R antagonists was identified by core replacement of the aminoquinoline lead 1. Subsequent modi. cation of the 2- and 5-positions led to improvement in potency and intrinsic clearance. Compound 25 exhibited good plasma and brain exposure, and attenuated MCH induced food intake at 30 mg/kg PO in rats. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.147
• 作为产物：
  描述：

  N-异丙基甲胺 、 2-氯-5-硝基-1H-1,3-苯并咪唑 以 1,4-二氧六环 为溶剂， 反应 15.0h， 生成 2-[isopropyl(methyl)amino]-6-nitro-1H-benzimidazole
  参考文献：
  名称：

  ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT

  摘要：

  公开号：

  EP1553089B1

文献信息

• [EN] DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS<br/>[FR] DIAMINO-PYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE L'ANGIOGENESE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003074515A1

  公开（公告）日：2003-09-12

  Benzimidazole derivatives of formula (I) , which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases. (I)

  本发明描述了公式(I)的苯并咪唑衍生物，它们作为TIE-2和/或VEGFR-2抑制剂是有用的。所描述的发明还包括制造这样的苯并咪唑衍生物的方法，以及使用它们在治疗增生性疾病中的方法。
• Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
  申请人：Moriya Minoru

  公开号：US20050222161A1

  公开（公告）日：2005-10-06

  This invention relates to a benzimidazole derivative of the general formula [I] [wherein B 1 , B 2 , and B 3 represent hydrogen atom or lower alkyl; R 1 and R 2 are same or different and represent lower alkyl, etc.; R 3 and R 4 represent hydrogen atom, etc.; W represents a 3 to 8-membered aromatic or alphatic heterocycle, etc.; and Ar represents a substituted or unsubstituted aromatic heterocycle, etc.] This compound functions as an antagonist to melanin-concentrating hormone receptor and is useful as a drug for central diseases, circulatory diseases and metabolic diseases.

  本发明涉及一种苯并咪唑衍生物，其一般式为[I] [其中B1，B2和B3代表氢原子或低碳基; R1和R2相同或不同，代表低碳基等; R3和R4代表氢原子等; W代表3至8个成员的芳香或脂肪族杂环等; Ar代表取代或未取代的芳香族杂环等] 该化合物作为黑色素浓缩激素受体的拮抗剂，并可用作中枢疾病、循环系统疾病和代谢性疾病的药物。
• ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1553089B1

  公开（公告）日：2009-09-30
• DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1487824A1

  公开（公告）日：2004-12-22
• Identification of 2-aminobenzimidazoles as potent melanin-concentrating hormone 1-receptor (MCH1R) antagonists
  作者：Minoru Moriya、Hiroyuki Kishino、Shunji Sakuraba、Toshihiro Sakamoto、Takuya Suga、Hidekazu Takahashi、Takao Suzuki、Masahiko Ito、Junko Ito、Ryuichi Moriya、Norihiro Takenaga、Hisashi Iwaasa、Akane Ishihara、Akio Kanatani、Takehiro Fukami

  DOI：10.1016/j.bmcl.2009.04.147

  日期：2009.7

  A series of 2-aminobenzimidazole-based MCH1R antagonists was identified by core replacement of the aminoquinoline lead 1. Subsequent modi. cation of the 2- and 5-positions led to improvement in potency and intrinsic clearance. Compound 25 exhibited good plasma and brain exposure, and attenuated MCH induced food intake at 30 mg/kg PO in rats. (C) 2009 Elsevier Ltd. All rights reserved.